UK-based wealth managers are uncertain what effect the new EU regulations will have on their relationships with clients.
Early 5G demos and launch commitments may be flashy, but they ignore a critical reality: regulation will play a much more critical role in the success of future 5G networks and services.
Another day, another drama at the BBC.
When the European Commission slapped Google with a €2.4bn ($2.7bn) fine for giving priority placement in search results to its own shopping service, it set a precedent other tech giants need to pay attention to.
Advertisements that promote sexist stereotypes should be banned under proposals put forward by the Advertising Standards Agency (ASA).
Legal Lean’s new Coco Loko infused raw cacao snuff is likely to go down as one of the most controversial new product launches since Palcohol’s powdered alcohol in 2014.
General Data Protection Regulation (GDPR) means the EU is getting serious in terms of protecting personal data and with potential fines of €20m or four percent of turnover, companies are nervous about the implications.
As Exxon Mobil’s Liza project moves into the development phase the challenge for the Guyana government is to strengthen the regulatory framework.
San Francisco has become the first city in the US to ban the sale of flavoured tobacco products, including menthol cigarettes.
The Grenfell disaster can be the last of its kind.
Mobile revenue has been struggling recently in Western Europe.
Kinder Joy eggs — Italian chocolatier Ferrero’s toy-in-a-chocolate similar to the well known Kinder Surprise — will soon be available in the US due to a change to the classic design.
There is bad news for global pharmaceutical and medical devices companies; China has developed a set-in-stone timetable to conduct government-driven price management and reimbursement controls.
The US Office of the Comptroller of the Currency (OCC) is in the midst of a heated battle with state regulators and the loss of its chief means plans to grant special purpose national bank charters to financial technology firms (fintechs) will collapse.
In developed markets, especially the US, pharmaceutical companies are facing a period of uncertainty, with pricing and reimbursements concerns causing significant barriers to revenue potential.
A regulatory advisory group — sponsored by the City of London Corporation and TheCityUK — has hatched a plan for the UK to retain EU market access post-Brexit.
The launch of the Markets in Financial Instruments Directive (MiFID) II is fast approaching.
A lot of negative chatter around energy drinks is unsubstantiated, but the sheer quantity of stories cannot be denied.
Cannabis is increasingly affecting all aspects of retail in the US.
It was announced today that BT has given in to the regulator Ofcom’s demands to legally separate from Openreach.
After many decades of prohibition doctors in the US now prescribe medical cannabis for a range of conditions, from HIV and Aids, to nausea and vomiting in cancer patients, pain and epilepsy.
The cryptocurrency bitcoin’s hit a milestone, and a quite a big one.
The Royal Bank of Scotland — still 73 percent tax-payer owned since the financial crisis — has just reported its ninth consecutive year of losses.
Today, some of the most popular online search engines including Google and Bing, promised to make it harder for users to access illegal streaming websites.
Oil investment is increasingly competitive with countries desperate for oil majors not to axe projects in their region.
US president Donald Trump has appointed Ajit Pai to head the Federal Communications Commission (FCC), and people are worried it means the death of net neutrality.
Tesco has made a surprising, and very bold move to acquire food wholesaler Booker for £3.7bn ($4.6bn) this morning.
Think Amazon combined with eBay combined with PayPal combined with Twitter – add to that a bank and wealth manager – that’s Alibaba Group for you, and not even in its entirety.
While beginning to take hold in West Europe, the sugar tax on soft drinks was still very much in its infancy in the US in 2016.
Over the past few months, there has been a great deal of speculation around what kind of impact Donald Trump‘s presidency will have on healthcare and the pharmaceutical industry.